NCT05178043: GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2 | 5 | US | Nivolumab, Opdivo, ONO-4538, BMS-936558, MDX1106, GT90001, PF-03446962 | Suzhou Kintor Pharmaceutical Inc, | Hepatocellular Carcinoma, HCC | 04/25 | 12/25 | | |
NCT03893695: Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) |
|
|
| Completed | 1/2 | 20 | RoW | GT90001 and Nivolumab, GT90001 and Opdivo | Suzhou Kintor Pharmaceutical Inc, | Metastatic Hepatocellular Carcinoma, HCC, Combinations of Drugs; Dependence | 05/22 | 09/22 | | |
NCT04984668: A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors |
|
|
| Recruiting | 1/2 | 216 | RoW | GT90001+KN046, GT90001/KN046 | Suzhou Kintor Pharmaceutical Inc,, Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Solid Tumor | 04/25 | 12/25 | | |
